LT3893B - Pharmaceutical composition with nalmefene for treating alcoholism - Google Patents

Pharmaceutical composition with nalmefene for treating alcoholism Download PDF

Info

Publication number
LT3893B
LT3893B LTIP1486A LTIP1486A LT3893B LT 3893 B LT3893 B LT 3893B LT IP1486 A LTIP1486 A LT IP1486A LT IP1486 A LTIP1486 A LT IP1486A LT 3893 B LT3893 B LT 3893B
Authority
LT
Lithuania
Prior art keywords
alcohol
nalmefene
patient
treatment
rats
Prior art date
Application number
LTIP1486A
Other languages
English (en)
Lithuanian (lt)
Inventor
John D Sinclair
Harry Scheinin
Risto Arvo Sakari Lammintausta
Original Assignee
Alko Ltd
Orion Corp Farmos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Ltd, Orion Corp Farmos filed Critical Alko Ltd
Publication of LTIP1486A publication Critical patent/LTIP1486A/xx
Publication of LT3893B publication Critical patent/LT3893B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
LTIP1486A 1990-06-04 1993-11-25 Pharmaceutical composition with nalmefene for treating alcoholism LT3893B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene

Publications (2)

Publication Number Publication Date
LTIP1486A LTIP1486A (en) 1995-09-25
LT3893B true LT3893B (en) 1996-04-25

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP1486A LT3893B (en) 1990-06-04 1993-11-25 Pharmaceutical composition with nalmefene for treating alcoholism

Country Status (19)

Country Link
US (1) US5086058A (fr)
EP (1) EP0531415B1 (fr)
JP (1) JP3059213B2 (fr)
AT (1) ATE145329T1 (fr)
AU (1) AU642748B2 (fr)
CA (1) CA2084519C (fr)
DE (1) DE69123247T2 (fr)
DK (1) DK0531415T3 (fr)
ES (1) ES2097209T3 (fr)
FI (1) FI925513A (fr)
GR (1) GR3022289T3 (fr)
HU (1) HU210637B (fr)
IE (1) IE77333B1 (fr)
LT (1) LT3893B (fr)
LV (1) LV10190B (fr)
NZ (1) NZ238391A (fr)
RU (1) RU2090190C1 (fr)
WO (1) WO1991018605A1 (fr)
ZA (1) ZA914185B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (fr) * 1995-11-20 1997-05-29 University Of Miami Procede pour traiter la dependance a la nicotine
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
JP2001526229A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド投薬剤形の乱用を防止する方法
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
HU1500214D0 (hu) 1997-12-22 2002-03-28 Euro Celtique Sa Opioid agonista és antagonista hatóanyagot tartalmazó gyógyszerkészítmény
EP1248800A2 (fr) * 1999-11-30 2002-10-16 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
OA12215A (en) 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
ATE540613T1 (de) * 2001-07-13 2012-01-15 Arkray Inc Analysevorrichtung und durchstechelement- integrierte verbindung für eine konzentrationsanalysevorrichtung
DE60230632D1 (de) * 2001-07-18 2009-02-12 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
IS7142A (is) 2001-08-06 2004-02-05 Euroceltique S.A. Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
EP2425823A1 (fr) 2002-04-05 2012-03-07 Euro-Celtique S.A. Préparation pharmaceutique contenant de l'oxycodone et de la naloxone
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
EP1551372B8 (fr) * 2002-09-20 2018-08-01 Alpharma Pharmaceuticals LLC Sous-unite de sequestration et compositions et procedes associes
EP1610791B1 (fr) * 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Dispositif polymere implantable pour liberation prolongee d'agoniste de la dopamine
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004229551A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
EP1702558A1 (fr) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
EP2526932B1 (fr) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Composition pharmaceutique
SI2724722T1 (sl) 2006-10-20 2017-07-31 Neurendo Pharma, Llc Postopek za obnovitev učinka inkretina
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
ATE523512T1 (de) * 2008-04-24 2011-09-15 Janssen Pharmaceutica Nv Nalmefen-prodrugs
KR101598138B1 (ko) * 2008-04-24 2016-02-29 얀센 파마슈티카 엔.브이. 날메펜 디에스테르 프로드럭
EP2317991B1 (fr) * 2008-07-07 2017-05-03 Euro-Celtique S.A. Utilisation d'antagonistes opioïdes pour le traitement d'une rétention urinaire
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
US20140005217A1 (en) * 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (fr) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalméfène pour le traitement de patients atteints de trouble du sommeil
CN105517551A (zh) 2013-07-23 2016-04-20 欧洲凯尔特公司 用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
US20170042887A1 (en) * 2014-04-22 2017-02-16 Otsuka Pharmaceutical. Co., Ltd. Combination of Brexpiprazole and Nalmefene and Use Thereof for Treating Substance-Related Disorders
EP3215154B1 (fr) 2014-11-07 2020-01-29 Regents of the University of Minnesota Sels et compositions utiles pour le traitement de maladie
EP3445363A1 (fr) * 2016-04-22 2019-02-27 Taiwanj Pharmaceuticals Co., Ltd. Nalméfène, naltrexone ou dérivés de ceux-ci destinés à être utilisés dans le traitement de la stéatohépatite non alcoolique ou de la maladie du foie gras d'origine non alcoolique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIXON AT AL.: "Clin.Pharmacol., Vol.27, 1987", pages: 233 - 239
YEOMANS ET AL.: "Psycopharmacology, vol. 100, 1990", pages: 426 - 432

Also Published As

Publication number Publication date
HU210637B (en) 1995-06-28
LV10190B (en) 1995-06-20
FI925513A0 (fi) 1992-12-04
JPH06506665A (ja) 1994-07-28
FI925513A (fi) 1992-12-04
GR3022289T3 (en) 1997-04-30
NZ238391A (en) 1997-06-24
HU9203835D0 (en) 1993-03-29
IE911888A1 (en) 1991-12-04
CA2084519C (fr) 1999-02-09
EP0531415B1 (fr) 1996-11-20
WO1991018605A1 (fr) 1991-12-12
EP0531415A1 (fr) 1993-03-17
LTIP1486A (en) 1995-09-25
AU642748B2 (en) 1993-10-28
JP3059213B2 (ja) 2000-07-04
ZA914185B (en) 1992-07-29
HUT65523A (en) 1994-06-28
AU7974091A (en) 1991-12-31
ES2097209T3 (es) 1997-04-01
IE77333B1 (en) 1997-12-03
RU2090190C1 (ru) 1997-09-20
CA2084519A1 (fr) 1991-12-05
LV10190A (lv) 1994-10-20
ATE145329T1 (de) 1996-12-15
DE69123247D1 (de) 1997-01-02
DE69123247T2 (de) 1998-01-15
US5086058A (en) 1992-02-04
DK0531415T3 (da) 1996-12-09

Similar Documents

Publication Publication Date Title
LT3893B (en) Pharmaceutical composition with nalmefene for treating alcoholism
Hoehn-Saric et al. Effects of clonidine on anxiety disorders
Oswald et al. Some experiments in the chemistry of normal sleep
Olson et al. Endogenous opiates: 1997
Papp et al. Toxic effects of iproniazid in a patient with angina
JP2013527132A (ja) 中枢神経系（ｃｎｓ）の自己免疫性脱髄性疾患の治療において使用するためのジアゾキシド
JP2008201796A (ja) アルコール依存症治療用の薬剤
EP0563336B1 (fr) Composition pharmaceutique contenant de l'acide gamma-hydroxybutyrique ou sa lactone et utilisee dans le traitement de la toxicomanie et des troubles nutritionnels
EP1681057A1 (fr) Utilisation de Naloxone pour traiter les troubles alimentaires
KR100425045B1 (ko) 약물중독의치료를위한멜라토닌함유약학적조성물
JP2007529547A (ja) アルコール中毒の処置方法
KR100712571B1 (ko) 코카인 중독증의 치료용 약제를 제조하기 위한플루마제닐의 용도
BG62876B1 (bg) Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост
Ferris et al. Neuropeptide modulation of cognition and memory in humans.
US20030064932A1 (en) Methods of treatment comprising administration of Substance P
Treiman et al. Increasing plasma concentration tolerability study of flunarizine in comedicated epileptic patients
US4861772A (en) Method and composition to treat panic syndrome
WO2017196857A1 (fr) Traitement de l'alcoolisme et de la dépression et/ou de l'humeur dysphorique avec de l'ibudilast
Nagain‐Domaine et al. Modulation by alcohol and methadone of 2‐deoxyglucose‐stimulated pancreatic secretion in the rat
Taylor Alcohol and the brain
FR2515044A1 (fr) Composition medicale pour controler le rythme biologique diurne et nocturne de l'organisme humain et plus specifiquement pour combattre les troubles sexuels de l'etre humain

Legal Events

Date Code Title Description
PC9A Transfer of patents

Free format text: CONTRAL CLINICS OY,TAPIOLAN KESKUSTORNI 6KRS, FIN-02100 ESPOO,FI,990910

MK9A Expiry of a patent

Effective date: 20131125